Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZoetisXSWX:ZTS +2.39%63 EV-to-EBIT is 11.32 as of Jul. 17, 2026, which is 58% below its 10-year median of 26.92. GuruFocus rates XSWX:ZTS with a GF Score™ of 63/100 and a GF Value™ of CHF156.38 (Significantly Undervalued). Among 689 Drug Manufacturers companies, Zoetis ranks better than 66.47% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Zoetis's Enterprise Value is CHF31,998 Mil.
Zoetis's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was CHF2,826 Mil. Therefore, Zoetis's EV-to-EBIT for today is 11.32.
The historical rank and industry rank for Zoetis's EV-to-EBIT or its related term are showing as below:
XSWX:ZTS'
s EV-to-EBIT Range Over the Past 10 Years
Min: 10.92 Med: 26.92 Max: 45.24
Current: 11.18
During the past 13 years, the highest EV-to-EBIT of Zoetis was 45.24. The lowest was 10.92. And the median was 26.92.
XSWX:ZTS's EV-to-EBIT is ranked better than 66.47% of 689
companies
in the Drug Manufacturers industry
Industry Median: 15.73
vs XSWX:ZTS: 11.18
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Zoetis's Enterprise Value for the quarter that ended in Mar. 2026 was CHF44,649 Mil.
Zoetis's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF2,826 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zoetis EV-to-EBIT Related Terms
Zoetis EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Zoetis's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ZTS vs UTHR, VTRS, NBIX: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zoetis's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zoetis EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zoetis's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Zoetis's EV-to-EBIT falls into.
Zoetis's current Enterprise Value is CHF31,998 Mil.
Zoetis's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF2,826 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zoetis (XSWX:ZTS) has a EV-to-EBIT of 11.32 as of Jul. 17, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Zoetis and its competitors. This is 58% below median its historical median of 26.92. Over the past decade, Zoetis' EV-to-EBIT has ranged from 10.92 to 45.24. According to the industry distribution chart, Zoetis ranks #231 out of 689 companies in the Drug Manufacturers industry, placing it in the top 33.5%.
Is Zoetis' EV-to-EBIT too high?
Zoetis' current EV-to-EBIT of 11.32 is 58% below median its 10-year median of 26.92. Over the past 10 years, this metric has ranged from a low of 10.92 to a high of 45.24. The Drug Manufacturers industry median EV-to-EBIT is 15.73. Zoetis' value of 11.32 is 28% below this industry median. Based on the distribution chart, Zoetis ranks #231 out of 689 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Zoetis has a GF Score™ of 63/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zoetis' EV-to-EBIT compare to UTHR and VTRS?
According to the Drug Manufacturers industry distribution chart, Zoetis ranks #231 out of 689 companies for EV-to-EBIT. This puts Zoetis in the upper half of its industry. The industry median EV-to-EBIT is 15.73. Zoetis' value of 11.32 is 28% below this benchmark. Historically, Zoetis' own EV-to-EBIT has ranged from 10.92 to 45.24 over the past decade. While the company's 10-year median is 26.92 vs. the industry median of 15.73, Zoetis has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.73, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zoetis's current EV-to-EBIT of 11.32 is 28% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Zoetis and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zoetis's current EV-to-EBIT is 11.32, which is 58% below median its own 10-year median of 26.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zoetis stock overvalued right now?
Based on GuruFocus' analysis, Zoetis (XSWX:ZTS) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF156.38, compared to a current price of CHF61.79 — trading 60.5% below its estimated fair value. The current EV-to-EBIT is 11.32, which is 58% below median its 10-year median of 26.92 and 28% below the Drug Manufacturers industry median of 15.73. Zoetis' overall GF Score™ is 63/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Zoetis (XSWX:ZTS), the current EV-to-EBIT is 11.32 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zoetis (XSWX:ZTS) Overvalued in 2026?
Based on GuruFocus' analysis, Zoetis stock appears to be undervalued.
The current stock price of CHF61.79 is trading 60.5% below its estimated GF Value™ of CHF156.38.
GuruFocus considers Zoetis to be Significantly Undervalued.
Key valuation signals for XSWX:ZTS:
EV-to-EBIT: 11.32 (58% below median its 10-year median of 26.92)
GF Value™: CHF156.38 vs. price of CHF61.79 (60.5% below fair value)
Industry Position: 28% below the Drug Manufacturers median (#231 of 689)
No single metric tells the full story. See the XSWX:ZTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
63GF Score
Get the complete analysis for XSWX:ZTS
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ZTS has been successfully added to your 
